Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

医学 曲妥珠单抗 内科学 析因分析 肿瘤科 Destiny(ISS模块) 事后 癌症 乳腺癌 物理 天文
作者
Ana Oaknin,Jung‐Yun Lee,Vicky Makker,Do‐Youn Oh,Susana N. Banerjee,Antonio González-Martı́n,Kyung Hae Jung,Iwona A. Lugowska,Luis Manso,Aránzazu Manzano,Bohuslav Melichar,Salvatore Siena,Daniil Stroyakovskiy,Anitra Fielding,Soham D. Puvvada,Ann Smith,Funda Meric‐Bernstam
出处
期刊:Advances in Therapy [Adis, Springer Healthcare]
卷期号:42 (5): 2015-2018 被引量:7
标识
DOI:10.1007/s12325-024-03080-9
摘要

of the original article, 'Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02'. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate, which is a chemotherapy with a linker (deruxtecan) joined to an antibody (trastuzumab). Trastuzumab binds to the human epidermal growth factor receptor 2 (HER2) protein on cancer cells, where it releases the chemotherapy to kill these cells. The DESTINY-PanTumor02 clinical study tested the effectiveness of T-DXd for people with various HER2-expressing cancers and the safety of treatment. Previous results from DESTINY-PanTumor02 showed that T-DXd had antitumor activity, and the greatest effects were seen in people with the highest tumor level of HER2 [defined as immunohistochemistry (IHC) 3+]. In this previous analysis, the HER2 expression was measured at a central laboratory. In clinical practice, HER2 expression will likely be measured at a local laboratory, so understanding whether T-DXd has similar effects regardless of how HER2 expression is measured is important. Here, we looked at the effects of T-DXd based on the HER2 test result used to determine a person's eligibility for the study, which could be measured using a local or central laboratory. In people with IHC 3+ tumors (where HER2 was measured at a local or central laboratory), 51% had a decrease in the size or number of tumors, according to established criteria (referred to as an objective response), while, in people with IHC 2+ tumors, 26% had an objective response. Side effects with T-DXd were consistent with previous studies. These results confirm T-DXd has antitumor effects in HER2-expressing cancers where the HER2 expression is measured by a local or central laboratory.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Code_king发布了新的文献求助10
1秒前
1秒前
Su发布了新的文献求助10
1秒前
1秒前
JRGuan完成签到,获得积分10
1秒前
含蓄觅山发布了新的文献求助10
1秒前
李健的粉丝团团长的应助被Birk采纳,获得10
1秒前
1秒前
1秒前
Code_king发布了新的文献求助10
1秒前
1秒前
秋风的应助被ddd采纳,获得20
1秒前
hh发布了新的文献求助10
1秒前
1秒前
Akim的应助被balalal采纳,获得10
2秒前
赵优秀发布了新的文献求助10
2秒前
Code_king发布了新的文献求助10
2秒前
2秒前
pmh完成签到,获得积分10
2秒前
科研通AI6.4的应助被srkb采纳,获得10
3秒前
小二郎的应助被Foremelon采纳,获得10
3秒前
3秒前
初景的应助被帅气皮皮虾采纳,获得20
3秒前
3秒前
3秒前
wait完成签到 ,获得积分10
3秒前
Code_king发布了新的文献求助10
3秒前
大模型的应助被顺顺利利采纳,获得10
3秒前
郁离完成签到 ,获得积分10
4秒前
无花果的应助被UnprofessionalX采纳,获得10
4秒前
Code_king发布了新的文献求助10
4秒前
4秒前
笛子发布了新的文献求助10
4秒前
hua发布了新的文献求助10
4秒前
4秒前
Code_king发布了新的文献求助10
4秒前
4秒前
Code_king发布了新的文献求助10
4秒前
Code_king发布了新的文献求助10
5秒前
Code_king发布了新的文献求助10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176102
求助须知:如何正确求助?哪些是违规求助? 9567588
关于积分的说明 21793477
捐赠科研通 7770603
什么是DOI,文献DOI怎么找? 3431969
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477522